Robert E. Landry
2021
Compensation breakdown
Non-Equity Incentive Plan | $1,052,182 |
---|---|
Option Awards | $3,839,805 |
Salary | $822,800 |
Stock Awards | $2,559,468 |
Other | $24,200 |
Total | $8,298,455 |
Landry received $3.8M in option awards, accounting for 46% of the total pay in 2021.
Landry also received $1.1M in non-equity incentive plan, $822.8K in salary, $2.6M in stock awards and $24.2K in other compensation.
Rankings
In 2021, Robert E. Landry's compensation ranked 1,380th out of 12,415 executives tracked by ExecPay. In other words, Landry earned more than 88.9% of executives.
Classification | Ranking | Percentile |
---|---|---|
All | 1,380 | 89th |
Manufacturing | 497 | 91st |
Chemicals And Allied Products | 181 | 92nd |
Drugs | 151 | 93rd |
Pharmaceutical Preparations | 100 | 94th |
Landry's colleagues
We found five more compensation records of executives who worked with Robert E. Landry at Regeneron Pharmaceuticals in 2021.
2021
Daniel Van Plew
Regeneron Pharmaceuticals
Executive Vice President and General Manager, Industrial Operations and Product Supply
2021
Andrew Murphy
Regeneron Pharmaceuticals
Executive Vice President, Research
2021
Joseph LaRosa
Regeneron Pharmaceuticals
General Counsel
2021
Leonard Schleifer
Regeneron Pharmaceuticals
Chief Executive Officer
2021
George Yancopoulos
Regeneron Pharmaceuticals
Chief Scientific Officer
News
April 21, 2022
April 23, 2021
April 24, 2020
April 26, 2019